| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/16/2014 | US20140017271 Immunogenic compositions of staphylococcus aureus antigens |
| 01/16/2014 | US20140017263 Delivery Agents for Targeted Treatment of Elastin Degradation |
| 01/16/2014 | US20140017261 Selection and treatment of subjects |
| 01/16/2014 | US20140017260 Methods and materials for reducing bone loss |
| 01/16/2014 | US20140017258 Compositions against bacterial toxins |
| 01/16/2014 | US20140017253 RSPO3 Binding Agents and Uses Thereof |
| 01/16/2014 | US20140017249 Methods for improvement of beta cell function |
| 01/16/2014 | US20140017248 Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection |
| 01/16/2014 | US20140017247 Composition for modulating the expression of cell adhesion molecules |
| 01/16/2014 | US20140017245 Klk-13 antibody inhibitor for treating dry eye |
| 01/16/2014 | US20140017241 Non-natural ribonuclease conjugates as cytotoxic agents |
| 01/16/2014 | US20140017240 Fully Human Antibodies Against N-Cadherin |
| 01/16/2014 | US20140017239 IGE CH3 Peptide Vaccine |
| 01/16/2014 | US20140017236 Methods for treating interleukin-6 related diseases |
| 01/16/2014 | US20140017235 Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| 01/16/2014 | US20140017233 Biological markers for identifying patients for treatment with vegf antagonists |
| 01/16/2014 | US20140017232 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 01/16/2014 | US20140017231 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 01/16/2014 | US20140017230 Chronic lymphocytic leukemia (cll) biomarkers |
| 01/16/2014 | US20140017204 Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity |
| 01/16/2014 | US20140017197 Anti-CD19 Antibodies |
| 01/16/2014 | US20140017170 Methods and compositions for localized agent delivery |
| 01/16/2014 | US20140017166 Material and methods for treating or preventing her-3 associated diseases |
| 01/16/2014 | CA2876730A1 Enhancing activity of car t cells by co-introducing a bispecific antibody |
| 01/15/2014 | EP2684959A1 Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof |
| 01/15/2014 | EP2684895A1 Crystalline anti-hTNFalpha antibodies |
| 01/15/2014 | EP2684889A2 Multivariable antigens complexed with targeting humanized monoclonal antibody |
| 01/15/2014 | EP2684572A1 Adjuvant composition containing citrulline |
| 01/15/2014 | EP2684571A1 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
| 01/15/2014 | EP2683741A2 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| 01/15/2014 | EP2683740A2 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| 01/15/2014 | EP2683738A1 Anti oligomer antibodies and uses thereof |
| 01/15/2014 | EP2683737A1 Extracellular targeted drug conjugates |
| 01/15/2014 | EP2683408A1 Conjugation process |
| 01/15/2014 | EP2683406A2 Anti-cd40 antibodies and uses thereof |
| 01/15/2014 | EP2683404A1 The method of treating amyotrophic lateral sclerosis |
| 01/15/2014 | EP2683403A1 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| 01/15/2014 | EP2683402A1 A method of vaccination comprising a histone deacetylase inhibitor |
| 01/15/2014 | EP2683401A1 Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine |
| 01/15/2014 | EP2683400A1 Listeria-based adjuvants |
| 01/15/2014 | EP2683397A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| 01/15/2014 | EP2683396A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| 01/15/2014 | EP2683377A1 Combination therapies for hematologic malignancies |
| 01/15/2014 | EP2282773B1 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| 01/15/2014 | EP1037926B1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/15/2014 | CN103517922A Antibodies directed against ICOS and uses thereof |
| 01/15/2014 | CN103517920A Anti - sclerostin antibody crystals and formulations thereof |
| 01/15/2014 | CN103517918A Antagonistic DR3 ligands |
| 01/15/2014 | CN103517717A Methods to enhance cell-mediated immunity |
| 01/15/2014 | CN103517716A Tolerogenic synthetic nanocarriers for inducing regulatory b cells |
| 01/15/2014 | CN103517715A North american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| 01/15/2014 | CN103517714A Methods and compositions of protein antigens for the diagnosis and treatment of toxoplasma gondii infections and toxoplasmosis |
| 01/15/2014 | CN103517713A Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| 01/15/2014 | CN103509838A High expression production process and extraction method of piglet escherichia coli K88, K99 and 987P cilium antigens |
| 01/15/2014 | CN103509815A Preparation method of recombinant panda IL-2 immune adjuvant |
| 01/15/2014 | CN103509732A Edwardsiella tarda natural low virulent strain and application thereof |
| 01/15/2014 | CN103509117A Bispecific antibody capable of resisting human epidermal growth factor receptor 2 (HER2) and human insulin-like growth factor-IR (IGF-IR), and preparation method and applications thereof |
| 01/15/2014 | CN103509116A 抗体纯化 Antibody Purification |
| 01/15/2014 | CN103509114A Monoclonal antibodies against claudin-18 for treatment of cancer |
| 01/15/2014 | CN103509113A Novel antibodies inhibiting c-MET dimerization, and uses thereof |
| 01/15/2014 | CN103509112A Novel antibodies inhibiting c-MET dimerization, and uses thereof |
| 01/15/2014 | CN103509111A Human anti-KIR antibodies |
| 01/15/2014 | CN103509110A Monoclonal antibodies against claudin-18 for treatment of cancer |
| 01/15/2014 | CN103509086A Function epitope of botulinum toxin, monoclonal antibody binding to its specificity and applications thereof |
| 01/15/2014 | CN103505729A Stable rabies virus humanized antibody combined reagent |
| 01/15/2014 | CN103505728A Inhibition of alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| 01/15/2014 | CN103505727A Application of novel function of CD146 targeted as co-receptor of vascular endothelial growth factor receptor-2 (VEGFR-2) in anti-tumor angiogenesis treatment |
| 01/15/2014 | CN103505726A Clinical scientific research formula for heart disease |
| 01/15/2014 | CN103505725A Universal influenza vaccine with broad-spectrum cross protection capability and preparation method thereof |
| 01/15/2014 | CN103505724A Swine fever and porcine pseudorabies bivalent vaccine as well as preparation method and application thereof |
| 01/15/2014 | CN103505723A Method for preparing freeze-dried rabies vaccine preparation |
| 01/15/2014 | CN103505476A Cell-free preparations of immunopotentiators, and preparation methods and uses thereof |
| 01/15/2014 | CN102988968B Vaccine utilizing vibrio anguillarum flagellin and application thereof |
| 01/15/2014 | CN102703388B Anti-human mCRP (monomeric C-reaction protein) monoclonal antibody, hybridoma cell lines and kit |
| 01/15/2014 | CN102333538B 免疫刺激性寡核苷酸 Immunostimulatory oligonucleotide |
| 01/15/2014 | CN102099468B Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| 01/15/2014 | CN101985036B Amyloid- beta (1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof |
| 01/15/2014 | CN101827611B Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent |
| 01/15/2014 | CN101809037B Human antibodies to human cd20 and method of using thereof |
| 01/14/2014 | USRE44704 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 01/14/2014 | US8629260 Anti-arthropod vector vaccines, methods of selecting and uses thereof |
| 01/14/2014 | US8629250 Hepcidin, hepcidin antagonists and methods of use |
| 01/14/2014 | US8629249 Streptococcus uberis adhesion molecule |
| 01/14/2014 | US8629248 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 01/14/2014 | US8629244 Interleukin-6 receptor binding polypeptides |
| 01/14/2014 | US8629117 Method for stimulating the immune system |
| 01/14/2014 | US8629100 Method of inhibiting clostridium difficile by administration of oritavancin |
| 01/14/2014 | US8628947 Potomac horse fever isolates |
| 01/14/2014 | US8628937 Vaccines with enhanced immune response and methods for their preparation |
| 01/14/2014 | US8628917 Genes of an otitis media isolate of nontypeable Haemophilus influenzae |
| 01/14/2014 | US8628809 Method of inducing mucosal immune response to antigen with Dioscorea polysaccharides adjuvant |
| 01/14/2014 | US8628786 Polychlorinated biphenyls and squalene-containing adjuvants |
| 01/14/2014 | US8628785 Method for augmenting the immunogenicity of an antigen |
| 01/14/2014 | US8628784 Adjuvant systems and vaccines |
| 01/14/2014 | US8628782 Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction |
| 01/14/2014 | US8628781 Prevention and treatment of cast nephropathy |
| 01/14/2014 | US8628780 Lutzomyia longipalpis polypeptides and methods of use |
| 01/14/2014 | US8628779 Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof |
| 01/14/2014 | US8628778 Humanized monoclonal antibodies to hepatocyte growth factor |
| 01/14/2014 | US8628777 Antibodies binding IL-1 related polypeptides |